Making a Career at Home is Contenting


With almost 40 million people Poland is an enormous potential market but considering the status of it's biotechnological industry it is a white spot. How much 'biotech' is there in Poland, the biggest of the EU candidate countries? EuroBioTechNews spoke with Prof. Tomasz Twardowski, president of the recently established Polish Federation of Biotechnology (PFB) about the brain drain problem, possible solutions and the benefits of making a career at home.

In which areas is the Polish biotechnology very active and which parts have not been sufficiently established yet?
The most efficient, and let's say the most 'powerful' activities take place in the molecular areas of biotechnology particulary in plant molecular biology and bioorganic chemistry. What is not functioning efficiently yet are the roles of the state authorities and the general logistics. This makes co-operation between academia and industry difficult. This regards in particular the transfer of innovative technologies and applications of scientific ideas into the practice. This is generally due to the problems correlated with the very restrictive national legislation and particularly to lack of knowledge of intellectual property rights.
Can you give us a short overview on the process how the PFB was founded? Who initiated it - the academic institutions or the biotech companies?
Unfortunately, and I'm saying this for a reason, the Polish Federation of Biotechnology was initiated and organised from academic institutions. We have received only minor input from the Polish industry. For basic reasons: the Polish biotechnology industry plays only a minor role in the Polish economy itself. We have quite a strong scientific society and a lot of people that are interested in and engaged with biotechnology at the academic level, but very few envisage themselves as industry biotechnologists. There used to be a strong classic biotechnology industry in Poland, but modern biotechnology is mostly in the hands of multinational companies. They actually don't conduct their research here, they are merely interested in the market.
What are the main milestones you would like to achieve for the Polish biotech companies in the next couple of years?
At first, we would like to establish a Polish industry which will be founded on national innovative technologies, that is Polish ideas. Secondly, we want to establish international cooperations and collaborations. Today there is a good co-operation between the Polish Acedemy of Sciences and the German Max Planck Society.
How do you plan to stop the so called 'brain drain' phenomenon - the problem that many Polish researches emigrate to western countries?
My idea might sound like a joke, but we will be looking and following what other western countries will do about it. This is because they have the same problem. We have a brain drain going from East to West. More and more people from Russia, the Ukraine and even from Vietnam and India apply for positions in Poland, Hungary and the Czech Republic. And again, scientist from these three countries are seeking positions in Germany, France and the UK. Many researchers in Germany on the other hand chose to do their research in the US. So this is a common problem. Ideas like those of the German Max Planck Society, to grant so called 'come back' research fellowships might help. The first part of such a fellowship is to go abroad, the second part grants money to establish the laboratory at home.
In your career you too have been with Roche in the USA and at the Max Planck Institute in Germany. What were your reasons to continue your career in Poland?
A career in Poland is more satisfying and also more pleasant. In my home country, with my mothertounge, my family and my friends - I feel at home. And I'm pursuing my career at home.
We thank you for the interesting interview, Prof Twadowski!



Polish antibody development and manufacturing specialist Mabion S.A. more than tripled its revenues in 2011 (€2.5m) compared to 2010 (€0.74m). The increase in turnover mainly resulted from stronger client demand for R&D services...



Polish company Bioton S.A (Warsaw) and Swiss-headquartered generics giant Actavis (Zug) have joined forces to shake up the €12bn world market for recombinant insulins and insulin analogues. At the end of January, Bioton Chairman...



Zug/Warsaw - The fourth largest generics producer and a polish biotech want to create a stir in the market for diabetes drugs. Swiss Actavis and Bioton from Warsaw announced that they have formed a joint venture company for the...



Krakow – Polish Selvita S.A., which offers preclinical drug development services to pharma companies, has been ranked as the No. 1 “Rising Star” of this year’s Fast50 contest. In the programme, analysts from Deloitte Technology...



Warsaw – Poland’s Bioton S.A. has announced it is investing €20m in a new production plant in Szczecin. The biotechnology company is planning to manufacture insulin injection devices in the facility. The project involves the...



Warsaw – Biotech experts want to make the development of pharmaceutical and medical innovations a priority in Poland. At the start of September, members of the Polish Technology Platform for Innovative Medicine recommended that...



Kraków – Selvita SA CEO Pawel Przewiezlikowski announced at the end of July that the Polish drug development and drug discovery service firm is close to achieving profitability. After bagging EUR3.7m through an IPO on Warsaw’s...



Warsaw – Researchers from Lodz and Poznan Universities say Poland needs to update its draft GMO law. “The national current legal situation is complicated,” Prof. Tomas Twardowski told EuroBiotechNews, stressing that while trade...



Krakow – Polish Selvita S.A. is going public. By May, the drug discovery specialist announced it had entered into definite agreements with investors to sell 2.7 million shares for a total of EUR3.75m, resulting in a market...



Szczecin/Greifswald – A team of physical chemists headed by Robert Hoylst from the Polish Academy of Science have improved a method for calculating the migration time of drugs or drug delivery devices introduced into the sol/gel...

Displaying results 1 to 10 out of 108

1-10 Next >

© 2007-2016 BIOCOM



Current issue

All issues

Product of the week


Stock list

All quotes


  • PLETHORA (UK)3.38 GBP12.67%
  • ALMIRALL (E)14.43 EUR7.93%


  • 4SC (D)2.59 EUR-20.31%
  • FORMYCON (D)20.15 EUR-4.37%


  • GALAPAGOS (B)51.86 EUR30.7%
  • NICOX (F)11.00 EUR28.7%
  • GENMAB (DK)1177.00 DKK22.2%


  • MOBERG PHARMA (S)38.00 SEK-21.8%
  • 4SC (D)2.59 EUR-21.5%
  • FORMYCON (D)20.15 EUR-18.0%


  • KARO BIO (S)30.60 SEK1981.6%
  • CHRONTECH PHARMA (S)0.34 SEK1600.0%
  • NICOX (F)11.00 EUR491.4%


  • BB BIOTECH (D)44.03 EUR-84.5%
  • BIOTEST (D)17.15 EUR-78.1%

No liability assumed, Date: 29.05.2016


All Events



Biomedica 2016

Basel (CH)

Chemspec Europe 2016